bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

urlAlias

moreOnThisArticles

sponsorType

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Chinese e-commerce giant JD.com has tied up with leading Chinese drugmaker Shanghai Pharmaceuticals to develop its online healthcare business, the drugmaker said in a filing on Monday.
The move reflects a growing rivalry between Chinese e-commerce firms over China’s fast-growing online healthcare market, with technology seen as a potential cure for a sector that is bogged down by high prices, snarling hospital queues and frequent allegations of corruption.
Larger rival Alibaba Group said it joined forces with US drugmaker Merck & Co last week to explore developing online health services such as warehousing logistics and health data analysis.
The sale of prescription drugs online in China is currently prohibited, but Beijing is expected to open up the market soon and is finalising the list of medicines that will be approved for online sale, industry sources said.
READ MORE: Doctor consultation app seeks to disrupt China's health care market
“The government has recently announced a series of policies to encourage the development of online pharmacy and we expect this area to be a huge market opportunity,” Shanghai Pharma said in a filing to the Hong Kong stock exchange.
A JD.com spokesman declined to give immediate comment.
China is a magnet for drugmakers, medical device firms and hospital operators looking to tap the world’s second-biggest pharmaceutical market, where spending is set to hit as much as $185 billion by 2018, according to estimates from IMS Health.
Shanghai Pharma added a note of caution, reflecting wider concern over regulation of the sector: “China’s online drug market is still at an early stage, and there are still some uncertainties around policies governing this sector,” it said.


Hong Kong stocks advance as investors turn to China amid Middle East uncertainty

Chinese chain Qdama, known for its night discounts, plans Hong Kong IPO

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Hong Kong stock rally fades as investors reassess China’s economic outlook

JD.com

China’s JD.com in online pharmacy tie-up with Shanghai Pharma

Originally specialising in electronics, JD.com is seeking to expand its e-commerce offerings. Photo: Reuters

Tech